News

Source — Source: TH ///Category — GS Paper 2 ///Published — 2026-02-16 ///Exam — Both Prelims and Mains ///Tags — Rapid Fire, Quick Facts For Prelims, General Science ///Source — Source: TH ///Category — GS Paper 2 ///Published — 2026-02-16 ///Exam — Both Prelims and Mains ///Tags — Rapid Fire, Quick Facts For Prelims, General Science ///

Source: TH · GS Paper 2

Nitric Oxide Against Drug-Resistant Pneumonia

A recent study shows that high‑dose inhaled nitric oxide (300 ppm) markedly reduces drug‑resistant pneumonia, a major ICU challenge in India. The finding offers a potential non‑antibiotic strategy to curb antimicrobial resistance, a priority under the National Action Plan on AMR.

2026-02-16

Published

Source: TH

Source

Quiz Questions

Article

Key Facts and Data Points

Intervention: High‑dose inhaled nitric oxide (NO) at 300 ppm.
Outcome: Significant reduction in drug‑resistant pneumonia cases in ICU settings.
Epidemiology: Drug‑resistant pneumonia accounts for ≈1 in 5 hospital pneumonias, especially in intensive care units.
Major Pathogens: Pseudomonas aeruginosa, Streptococcus pneumoniae, MRSA, Klebsiella pneumoniae.
Clinical Impact: Delayed response, prolonged hospital stay, higher risk of sepsis and mortality.

Background and Context

Antimicrobial Resistance (AMR): Recognised by WHO and the Government of India as a critical public health threat. Over‑use of antibiotics in hospitals fuels resistant strains.
Nitric Oxide (NO): A colorless, short‑lived free radical produced endogenously from L‑arginine by nitric oxide synthases (NOS). Functions include:
Vasodilation – lowers blood pressure, improves tissue perfusion.
Neurotransmission – modulates synaptic plasticity.
Immune defence – exhibits antimicrobial and antitumor activity.
Therapeutic Relevance: The discovery of NO as the endothelium‑derived relaxing factor earned the 1998 Nobel Prize in Physiology or Medicine.

Significance for India / Governance / Policy

Healthcare: Adoption of inhaled NO could reduce ICU length of stay and antibiotic consumption, easing the burden on tertiary hospitals.
Policy Alignment: Supports the National Action Plan on Antimicrobial Resistance (NAP‑AMR, 2017‑2025) which emphasizes research on alternative therapies and stewardship.
Regulatory: Requires evaluation by the Drug Controller General of India (DCGI) and inclusion in clinical guidelines by bodies such as IAP (Indian Association of Pediatrics) and ICMR.
Economic Impact: Potential cost‑savings from reduced antibiotic use and shorter hospitalisation, aligning with Ayushman Bharat objectives of affordable care.

Related Constitutional / Legal Provisions

Article 21 (Right to Life & Health): Ensures access to effective medical treatment; innovative therapies like inhaled NO can be viewed under this right.
National Health Policy 2017: Emphasises research and development in emerging health technologies.

References

Study on high‑dose inhaled NO (2026).
National Action Plan on Antimicrobial Resistance, Ministry of Health & Family Welfare.
Nobel Prize 1998 – Discovery of NO as EDRF.